Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,412.59 -12.26 -0.07%
S&P 500 1,861.53 -0.78 -0.04%
NASDAQ 4,091.29 5.06 0.12%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human



  LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research
  Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored
  by GeneCards® Scientists

  Report shows the existence of ∼80,000 human non-redundant non-coding RNAs
covering 71% of the human genome, slightly less than the ENCODE prediction of
                                     80%

Business Wire

ALAMEDA, Calif. -- January 30, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the publication of a paper authored by a research group under
the supervision of Prof. Doron Lancet from the Department of Molecular
Genetics at the Weizmann Institute of Science describing the analysis and
display of a non-redundant compendium of human non-coding RNA genes, which was
made available as part of GeneCards^® Version 3.09, released November 18,
2012. LifeMap Sciences holds the exclusive worldwide license to market
GeneCards^® from Yeda Research and Development Company Ltd., the commercial
arm of the Weizmann Institute of Science.

Non-coding RNA (ncRNA) genes are increasingly acknowledged for their
importance in the human genome, and are implicated in various disease
processes. Therefore they are of interest to many academic and industry
researchers in various biomedical fields, and to biotechnology and
pharmaceutical companies engaged in discovery and development of diagnostic
and therapeutic products. The ENCODE project (www.genome.gov/10005107),
launched in 2003 has recently predicted that ~80% of all genomic territories
are transcribed in one fashion or another. In the GeneCards^® publication, in
the journal Bioinformatics (www.ncbi.nlm.nih.gov/pubmed/23172862), the
scientists leveraged the effective platform of GeneCards^® to unify all ncRNA
gene entries obtained from 15 different primary data sources. Overlapping
entries were clustered to unified locations based on an algorithm employing
genomic coordinates, resulting in a ∼5-fold increase, to a total of ∼80,000
human non-redundant ncRNAs, belonging to 14 classes. The total genome
territory covered is 71% of the human genome, slightly less than the ENCODE
prediction. This difference may be due to dataset input and computation
discrepancies or may represent ncRNA genes still awaiting identification and
characterization.

GeneCards^® is a comprehensive online database that provides concise genomic
information on all known and predicted human genes. With over 12 million page
visits per year from hundreds of thousands of unique users worldwide,
GeneCards^® is accessed by professionals in academia, research hospitals,
patent offices, and leading biotech and pharma companies. GeneCards^® was
developed, and is continuously enhanced by ongoing research, by the
bioinformatics team at the Department of Molecular Genetics at the Weizmann
Institute of Science in Israel, with principal investigator Professor Doron
Lancet, head of the Crown Human Genome Center, and team leader Marilyn Safran.

“It is wonderful to see how GeneCards^® allowed us to overcome the great
obstacles of grand unification of ncRNA genes. This allows scientists to make
discoveries on biological and disease-related roles for genes belonging to
this newly open vista of the human genome,” said Professor Doron Lancet,
Ph.D., The Ralph D. and Lois R. Silver Professor of Human Genomics, at the
Weizmann Institute of Science.

“The addition of detailed annotated ncRNAs information, while providing the
big picture on ncRNAs is a significant addition to GeneCards^®,” stated Yaron
Guan-Golan, Head of Marketing at LifeMap Sciences. “We have already seen
substantial interest from companies and academic users to access this new
information for their research and product discovery efforts. We believe that
this new information, and the synergies between GeneCards^®, MalaCards, and
LifeMap Discovery^TM will significantly enhance basic research, and contribute
greatly to the discovery and development of novel diagnostic and therapeutic
products and technologies.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. BioTime Acquisition Corporation is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

About the Weizmann Institute of Science and GeneCards

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 2,700 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and
scientific, technical and administrative staff. In addition, visiting
scientists and their families – over 500 from 35 countries in 2010 are
regularly hosted at the Institute. The Institute was founded in 1934 following
a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who
envisioned the establishment of a world-class scientific research center in
Israel, and later also became the first President of the State of Israel.
Weizmann Institute’s Feinberg Graduate School was established in 1958, where
about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the
Institute’s 18 departments, which are grouped into five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is currently
one of the most successful worldwide. Institute research efforts include the
search for new ways of fighting disease and hunger, examining leading
questions in mathematics and computer science, probing the physics of matter
and the universe, creating novel materials and developing new strategies for
protecting the environment. Particular excellence in bioinformatics and
systems biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of
Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by
Marilyn Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 worldwide web
resources.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390, ext 367
pgarcia@biotimemail.com
or
Judith Segall
510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap Sciences, Inc.
Kenneth Elsner
COO
781- 826- 7719
ke@lifemapsc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement